Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.97
AZN's Cash to Debt is ranked higher than
60% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. AZN: 0.97 )
AZN' s 10-Year Cash to Debt Range
Min: 0.35   Max: 8.68
Current: 0.97

0.35
8.68
Equity to Asset 0.42
AZN's Equity to Asset is ranked higher than
50% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. AZN: 0.42 )
AZN' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.59
Current: 0.42

0.31
0.59
Interest Coverage 7.50
AZN's Interest Coverage is ranked higher than
51% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 90.51 vs. AZN: 7.50 )
AZN' s 10-Year Interest Coverage Range
Min: 6.94   Max: 100.5
Current: 7.5

6.94
100.5
F-Score: 5
Z-Score: 2.96
M-Score: -2.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 14.44
AZN's Operating margin (%) is ranked higher than
82% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. AZN: 14.44 )
AZN' s 10-Year Operating margin (%) Range
Min: 12.32   Max: 38.09
Current: 14.44

12.32
38.09
Net-margin (%) 9.94
AZN's Net-margin (%) is ranked higher than
78% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. AZN: 9.94 )
AZN' s 10-Year Net-margin (%) Range
Min: 6.86   Max: 29.72
Current: 9.94

6.86
29.72
ROE (%) 11.01
AZN's ROE (%) is ranked higher than
84% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. AZN: 11.01 )
AZN' s 10-Year ROE (%) Range
Min: 11.01   Max: 42.95
Current: 11.01

11.01
42.95
ROA (%) 4.57
AZN's ROA (%) is ranked higher than
74% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. AZN: 4.57 )
AZN' s 10-Year ROA (%) Range
Min: 4.57   Max: 20.19
Current: 4.57

4.57
20.19
ROC (Joel Greenblatt) (%) 63.80
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. AZN: 63.80 )
AZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 22.94   Max: 199.14
Current: 63.8

22.94
199.14
Revenue Growth (%) -3.80
AZN's Revenue Growth (%) is ranked higher than
55% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. AZN: -3.80 )
AZN' s 10-Year Revenue Growth (%) Range
Min: -53.3   Max: 90
Current: -3.8

-53.3
90
EBITDA Growth (%) -13.30
AZN's EBITDA Growth (%) is ranked higher than
55% of the 504 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. AZN: -13.30 )
AZN' s 10-Year EBITDA Growth (%) Range
Min: -41.4   Max: 115.2
Current: -13.3

-41.4
115.2
EPS Growth (%) -28.50
AZN's EPS Growth (%) is ranked higher than
50% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. AZN: -28.50 )
AZN' s 10-Year EPS Growth (%) Range
Min: -28.5   Max: 73.6
Current: -28.5

-28.5
73.6
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

AZN Guru Trades in Q1 2013

Steven Cohen 8,894 sh (New)
NWQ Managers 78,400 sh (New)
Jim Simons 3,627,000 sh (+44.94%)
Pioneer Investments 761,116 sh (+44.64%)
Joel Greenblatt 93,261 sh (+11.06%)
HOTCHKIS & WILEY 2,138,888 sh (+8.84%)
David Dreman 164,649 sh (+7.96%)
Manning & Napier Advisors, Inc 509,072 sh (+5.65%)
Charles Brandes 2,039,355 sh (-6.82%)
John Hussman 932,000 sh (-38.8%)
» More
Q2 2013

AZN Guru Trades in Q2 2013

Murray Stahl 12,000 sh (New)
HOTCHKIS & WILEY 4,944,742 sh (+131.18%)
Steven Cohen 11,966 sh (+34.54%)
NWQ Managers 85,850 sh (+9.5%)
Charles Brandes 2,206,222 sh (+8.18%)
David Dreman 171,709 sh (+4.29%)
Manning & Napier Advisors, Inc 511,667 sh (+0.51%)
Joel Greenblatt Sold Out
Jim Simons 3,425,700 sh (-5.55%)
Pioneer Investments 477,061 sh (-37.32%)
John Hussman 375,000 sh (-59.76%)
» More
Q3 2013

AZN Guru Trades in Q3 2013

Steven Cohen 532,113 sh (+4346.87%)
Pioneer Investments 590,122 sh (+23.7%)
Charles Brandes 2,381,040 sh (+7.92%)
David Dreman 179,261 sh (+4.4%)
Murray Stahl 12,020 sh (+0.17%)
NWQ Managers 85,850 sh (unchged)
Manning & Napier Advisors, Inc 508,945 sh (-0.53%)
HOTCHKIS & WILEY 4,912,449 sh (-0.65%)
Jim Simons 2,913,800 sh (-14.94%)
John Hussman 68,000 sh (-81.87%)
» More
Q4 2013

AZN Guru Trades in Q4 2013

Francis Chou 13,000 sh (New)
Stanley Druckenmiller 360,500 sh (New)
Pioneer Investments 651,839 sh (+10.46%)
Charles Brandes 2,503,848 sh (+5.16%)
Steven Cohen 533,262 sh (+0.22%)
Murray Stahl 12,020 sh (unchged)
NWQ Managers 85,450 sh (-0.47%)
Manning & Napier Advisors, Inc 490,878 sh (-3.55%)
Jim Simons 2,715,400 sh (-6.81%)
HOTCHKIS & WILEY 3,689,214 sh (-24.9%)
David Dreman 106,975 sh (-40.32%)
John Hussman 28,000 sh (-58.82%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Dreman 2013-12-31 Reduce -40.32%0.34%$49.72 - $59.5 $ 63.5317%106975
John Hussman 2013-12-31 Reduce -58.82%0.11%$49.72 - $59.5 $ 63.5317%28000
John Hussman 2013-09-30 Reduce -81.87%0.66%$47.88 - $52.08 $ 63.5326%68000
Charles Brandes 2013-09-30 Add 7.92%0.12%$47.88 - $52.08 $ 63.5326%2381040
John Hussman 2013-06-30 Reduce -59.76%1.02%$47.22 - $53.01 $ 63.5325%375000
Joel Greenblatt 2013-06-30 Sold Out 0.24%$47.22 - $53.01 $ 63.5325%0
John Hussman 2013-03-31 Reduce -38.8%0.74%$44.67 - $50.06 $ 63.5334%932000
Charles Brandes 2012-12-31 New Buy1.2%$44.34 - $48.9 $ 63.5336%2188735
John Hussman 2012-12-31 Reduce -24.49%0.56%$44.34 - $48.9 $ 63.5336%1523000
David Dreman 2012-12-31 Reduce -52.4%0.2%$44.34 - $48.9 $ 63.5336%152504
Joel Greenblatt 2012-12-31 Reduce -31.34%0.12%$44.34 - $48.9 $ 63.5336%83972
Charles Brandes 2012-09-30 Sold Out 1.2%$44.91 - $48.35 $ 63.5336%0
Joel Greenblatt 2012-09-30 Add 42.7%0.12%$44.91 - $48.35 $ 63.5336%122294
David Dreman 2012-09-30 Reduce -24.31%0.11%$44.91 - $48.35 $ 63.5336%320376
Joel Greenblatt 2012-03-31 Add 66.8%0.12%$44.18 - $48.58 $ 63.5348%74557
Joel Greenblatt 2011-12-31 New Buy0.25%$42.53 - $49.89 $ 63.5338%44699
Joel Greenblatt 2011-06-30 Sold Out 0.33%$46.6 - $52.4 $ 63.5327%0
Bruce Berkowitz 2011-06-30 Sold Out 0.05%$46.6 - $52.4 $ 63.5327%0
Joel Greenblatt 2011-03-31 Reduce -51.77%0.35%$45.4 - $49.38 $ 63.5333%23900
Bruce Berkowitz 2011-03-31 New Buy0.05%$45.4 - $49.38 $ 63.5333%155000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 13.10
AZN's P/E(ttm) is ranked higher than
91% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.60 vs. AZN: 13.10 )
AZN' s 10-Year P/E(ttm) Range
Min: 5.2   Max: 29.51
Current: 13.1

5.2
29.51
P/B 1.40
AZN's P/B is ranked higher than
82% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. AZN: 1.40 )
AZN' s 10-Year P/B Range
Min: 0   Max: 7.08
Current: 1.4

0
7.08
P/S 3.10
AZN's P/S is ranked higher than
81% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. AZN: 3.10 )
AZN' s 10-Year P/S Range
Min: 1.41   Max: 4.47
Current: 3.1

1.41
4.47
PFCF 11.10
AZN's PFCF is ranked higher than
93% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.79 vs. AZN: 11.10 )
AZN' s 10-Year PFCF Range
Min: 4.3   Max: 38.24
Current: 11.1

4.3
38.24
EV-to-EBIT 14.10
AZN's EV-to-EBIT is ranked higher than
77% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. AZN: 14.10 )
AZN' s 10-Year EV-to-EBIT Range
Min: 4.3   Max: 22.7
Current: 14.1

4.3
22.7
PEG 2.40
AZN's PEG is ranked higher than
66% of the 309 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. AZN: 2.40 )
AZN' s 10-Year PEG Range
Min: 0.29   Max: 13.33
Current: 2.4

0.29
13.33
Shiller P/E 11.60
AZN's Shiller P/E is ranked higher than
93% of the 363 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.59 vs. AZN: 11.60 )
AZN' s 10-Year Shiller P/E Range
Min: 7.52   Max: 36.54
Current: 11.6

7.52
36.54

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.41
AZN's Dividend Yield is ranked higher than
96% of the 418 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.38 vs. AZN: 4.41 )
AZN' s 10-Year Dividend Yield Range
Min: 1.49   Max: 6.79
Current: 4.41

1.49
6.79
Dividend Payout 1.37
AZN's Dividend Payout is ranked lower than
71% of the 376 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. AZN: 1.37 )
AZN' s 10-Year Dividend Payout Range
Min: 0   Max: 0
Current: 1.37

Yield on cost (5-Year) 4.50
AZN's Yield on cost (5-Year) is ranked higher than
91% of the 429 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. AZN: 4.50 )
AZN' s 10-Year Yield on cost (5-Year) Range
Min: 1.49   Max: 6.79
Current: 4.5

1.49
6.79
Share Buyback Rate 4.60
AZN's Share Buyback Rate is ranked higher than
94% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.70 vs. AZN: 4.60 )
AZN' s 10-Year Share Buyback Rate Range
Min: 43.7   Max: -144.8
Current: 4.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.00
AZN's Price/DCF (Projected) is ranked higher than
86% of the 349 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. AZN: 1.00 )
AZN' s 10-Year Price/DCF (Projected) Range
Min: 0   Max: 0
Current: 1

Price/Median PS Value 1.30
AZN's Price/Median PS Value is ranked higher than
52% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. AZN: 1.30 )
AZN' s 10-Year Price/Median PS Value Range
Min: 0   Max: 0
Current: 1.3

Earnings Yield (Greenblatt) 7.10
AZN's Earnings Yield (Greenblatt) is ranked higher than
81% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. AZN: 7.10 )
AZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.4   Max: 23.5
Current: 7.1

4.4
23.5
Forward Rate of Return (Yacktman) 4.77
AZN's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. AZN: 4.77 )
AZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.9   Max: 29
Current: 4.77

4.9
29

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:AZN.Sweden, AZNDF.USA, AZN.UK, ZEGA.Germany, ZEG.Germany, AZNCF.USA
AstraZeneca PLC is engaged in the global, prescription-based biopharmaceutical business. Its pharmaceuticals business consists of the discovery and development of new products, which are then manufactured, marketed and sold. It focuses on six therapy areas of healthcare such as Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory & Inflammation. The Company has operations in the United Kingdom, Continental Europe, The Americas, Asia, Africa, and Australia.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide